Global Asthma and COPD Drugs Market Size & Growth Analysis Report, 2020-2026

The global market for asthma and chronic obstructive pulmonary disease (COPD) drugs is estimated to have a significant CAGR during the forecast period. The market is mainly driven due to increasing prevalence of respiratory diseases such as asthma and COPD across the globe coupled with growing R&D for the development of new drugs. Asthma is one of the major respiratory diseases that has affected almost every major economy across the globe. During an asthma attack, the lining of the bronchial tubes swells, which results in narrowing of airways and reduced flow of air through lungs. According to the Global Asthma Report 2018, Asthma affects 339 million people across all regions. It is one of the major causes of death and disability as nearly 1,000 people lost their lives each day due to asthma. Moreover, it was estimated that 3.17 million mortalities were caused due to COPD in 2015, which is 5% of all the mortalities across the globe in 2016.Therefore significant number of asthma and COPD contribute in the market.

To Request a Sample of our Report on Global Asthma and COPD Drugs Market:  https://www.omrglobal.com/request-sample/asthma-and-copd-drugs-market

The global asthma and COPD drugs market is segmented based on disease type and application. Based on the disease type, the market is further classified into asthma and COPD. The asthma segment is projected to have considerable share owing to the high demand of drug treatment in asthma coupled with growing asthma across the globe. Based on the drug class, the global asthma and COPD drugs market is further segmented into anti-inflammatory drugs, combination drugs, monoclonal antibodies, bronchodilators. 

(Get 15% Discount on Buying this Report)

A full Report of Global Asthma and COPD Drugs Market is Available at:  https://www.omrglobal.com/industry-reports/asthma-and-copd-drugs-market

Global Asthma and COPD Drugs Market Segmentation

By Disease Type

  • Asthma 
  • COPD

By Drug class

  • Anti-inflammatory Drugs
  • Combination Drugs
  • Monoclonal Antibodies
  • Bronchodilators

(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)